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ABSTRACT 
Background:  Rice  Bran  Arabinoxylan  Compound  (RBAC)  is  a  nutritional  supplement 
produced by enzymatic hydrolysis of hemicellulose B derived from rice bran. Several in vitro 
studies and clinical reports have shown RBAC to possess promising immunomodulating effects, 
specifically  with  respect  to  natural  killer  cell  and  cytokine  activity.  The  concept  of  a  true 
immunomodulator is an agent possessing a broad range of activity dependent upon the existing 
state  of  health  and  immunity  in  the  individual  host.  The  present  study  investigated  the 
immunomodulatory  effect  of  RBAC  in  a  healthy  adult  human  population  over  60  days  by 
assessing changes in natural killer cell cytotoxicity (NKCC) and cytokines and growth factors.  
Subjects  participated  in  a  two-group,  randomized  intervention,  where  one  group  (n=10) 
consumed 1 gram/day and the other (n=10) consumed 3 gram/day. Safety and tolerability of 
RBAC were assessed with total bilirubin, total protein, creatinine, and liver function tests. 
 
Results:  We found that both groups had similar responses for NKCC, cytokines, and growth 
factors.  The  NKCC  peaked  at  1  week,  whereas  interferon-γ,  tumor  necrosis  factor-α, 
interleukins-1α, -1β, -8, and -10, and epidermal growth factor peaked at 30 days. All subjects 
tolerated the supplement without any adverse reactions. 
 
Conclusions:  Our results showed transient, bi-directional, immune marker effects consistent 
with  true,  multifactorial  immunomodulation  rather  than  simply  immunostimulation  or 
immunosuppression. Given our findings, the immunomodulatory activity of RBAC merits study Functional Foods in Health and Disease 2012, 2(7):265-279                                                            Page 266 of 279 
in conditions where the immune system is functionally compromised (e.g., otherwise-healthy 
smokers and HIV/AIDS or cancer patients). RBAC may not only help to destroy tumor cells and 
viruses directly, but also increase the activity of immune cells, thereby optimizing the immune 
system, especially NKCC, which can increase the chance and speed of host recovery. 
 
Keywords: Rice bran, arabinoxylan compound, activity of immune cells, immunomodulation, 
HIV/AIDS, and cancer 
 
BACKGROUND 
Natural Killer Cells. The understanding of natural killer (NK) cells has evolved considerably 
since their initial characterization in 1975 as large granular cytotoxic lymphocytes of the innate 
immune system. While they lack antigen-specific cell surface receptors, NK cells possess the 
ability  to  recognize  and  destroy  transformed  cells.  This  is  accomplished  via  the  release  of 
granzyme and perforin granules, which act to induce cell death through apoptosis. To modulate 
their  cytotoxic  actions  and  maintain  tolerance  for  normal  human  cells,  NK  cells  possess  a 
diversity of activating and inhibitory receptors. 
Cells  transformed  by  viral  invasion  or  malignant  progression  can  be  identified  and 
eliminated  in  their  nascent  stages  by  various  immune  effector  cells  [1].  Animal  and  human 
studies show that NK cells play a central role in the immuno-surveillance of transformed cells 
[2;3]. The majority of the NK cell population exists in a resting state. Thus, peripheral blood NK 
cell count provides little correlation with efficacy, and NK cell cytotoxicity (NKCC) is typically 
utilized to monitor levels of NK cell function [4]. 
NK cell functions also include the production of pro-inflammatory and immunosuppressive 
cytokines,  including:    interferon-gamma  (IFN-γ),  tumor  necrosis  factor-alpha  (TNF-α), 
monocyte  chemotactic  protein-1  (MCP-1;  a.k.a.  CCL2),  and  interleukin  (IL)-10.  Tumor  cell 
identification and elimination are further facilitated by the actions of IFNs and other factors [5]. 
Macrophage and T cell responses are also modulated via the generation of IFN-γ and IL-10 by 
NK cells. 
Immunomodulation.  An immunomodulator may be defined as a substance that modulates 
the response of the immune system in its protection of the host organism. In the human body, 
this effect may involve augmenting or reducing the activation of specialized cells, antibodies, or 
immunochemical  (e.g.,  cytokines)  production  and  other  specific  modifications  of  the  body’s 
environment and physiology. 
Rice  Bran  Arabinoxylan  Compound  (RBAC)  is  a  commercially-available  medicinal 
glyconutrient complex. In the literature, it appears under several trade names (including MGN-3 
and Biobran) with demonstrated immunomodulator activity in vivo in mice and humans and in 
vitro in cancer cell lines [6-8]. 
In  vitro  studies  have  shown  that  varying  RBAC  concentrations  enhance  macrophage 
phagocytic activity and the activities of IFN-γ, TNF-α, and IL-6 cytokines [8;9]. However, the 
effect of RBAC in the normal, healthy population remains largely unknown. Given the potential 
for human health benefit apparent in prior clinical case and biologic mechanistic studies, it is 
clear that thorough investigation of RBAC immunomodulator activity is warranted [10]. In this Functional Foods in Health and Disease 2012, 2(7):265-279                                                            Page 267 of 279 
pilot study, we investigated the effect of a 60-day course of RBAC on NKCC, cytokines, and 
growth factors in a sample of healthy adults. Adverse reactions were monitored, along with total 
bilirubin, total protein, creatinine, and liver function tests to reconfirm existing documentation of 
safety and tolerance in humans. 
 
METHODS 
Study Participants.  Participants (n = 20) were recruited by referrals at the University of Miami 
Miller School  of Medicine during 2010. The study was  conducted with the approval  of the 
University of Miami Institutional Review Board for human subjects research, and all participants 
signed informed consent and HIPAA forms before participating in the study. The sample was 
comprised of 40% males (n = 8) and 60% females (n = 12) with a mean age of 33.6 years 
(Standard Deviation = 13.2; Range = 20, 66). The racial/ethnic distributions of the subjects were 
as follows:  55% white, non-Hispanic (n = 11), 35% Hispanic (n = 7), and 10% Asian/Pacific 
Islander (n = 2). 
Intervention.  RBAC (Daiwa Pharmaceutical Inc., Tokyo, Japan) is a nutritional supplement 
that contains an active ingredient patented and manufactured exclusively since 1990.  It is sold as 
a functional food in Japan. RBAC is an oligosaccharide complex produced via hydrolysis of rice 
bran hemicellulose B by Lentinula edodes, Coriolus versicolor, and Schizophyllum commune 
mycelia enzyme activity. It is spray-dried into a water-soluble powder and contains the following 
excipients:  microcrystalline cellulose, hypromellose, sucrose fatty  acid ester, and potassium 
acetate. The result is an oligosaccharide complex principally consisting of arabinose and β-1,4-
xylopyranose moieties with lesser quantities of other polysaccharide chains, including β-glucans. 
Subjects participated in a two-group, randomized intervention. The dosage range recommended 
by the manufacturer is 1-3 gram/day; therefore one group was given 1 gram/day (n = 10) and the 
second  group  given  3  gram/day  (n  =  10)  for  60  days.  All  participants  completed  the  study 
without any attrition. 
Assessments,  Sample  Collection,  and  Processing.  Each  participant  completed  a  basic 
demographics and medical history questionnaire at the baseline assessment. Venous blood was 
obtained at 5 different time points (baseline, 48 hours, 1 week, 30 days, and 60 days). Blood 
samples  were  collected  into  heparin,  SST,  and EDTA  tubes  and  delivered  to  the  laboratory 
within 2 hours of collection. All EDTA blood specimens were subjected to complete blood cell 
counts  and  auto  5-part  differential  count  determinations  by  a  fully-automated  Coulter  AcT5 
hematology analyzer (Beckman Coulter, Fullerton, CA). Flow cytometric enumeration of T, B, 
and  NK  cell  subsets  were  performed  on  a  4-color  flow  cytometer,  FACS  Calibur  (BD 
Biosciences, San Jose, CA), and the different cell populations were analyzed using Cell Quest 
Pro software (version 5.2, BD Biosciences, San Jose, CA). 
Peripheral  blood  mononuclear  cells  (PBMC)  were  isolated  by  Ficoll-Hypaque  gradient 
centrifugation.  PBMC  were  recovered  from  the  gradient  interface  and  washed  in  phosphate 
buffered saline. Blood was diluted with 1:1 RPMI 1640 (Gibco, Grand Island, NY), layered over 
Ficoll-Hypaque solution (Pharmacia, Piscataway, NJ), and centrifuged for 30 minutes at 1,500 
rpm at ambient temperature. The PBMC were collected, washed with RPMI 1640, and counted 
and assessed for viability in trypan blue dye. Plasma for cytokine detection was separated and Functional Foods in Health and Disease 2012, 2(7):265-279                                                            Page 268 of 279 
stored at -80°C till used. Total bilirubin, total protein, creatinine, alanine transaminase (ALT), 
aspartate aminotransferase (AST), and alkaline phosphatase (ALP) were assessed on an Olympus 
AU5400  chemistry  auto-analyzer,  which  uses  multi-wavelength  diffraction  grating 
spectrophotometry. 
Flow Cytometry-Based NKCC Assay.  The NKCC assay by flow cytometry was performed 
based on two previously published methods with some modifications [11;12]. K562 cells were 
purchased  from  American  Type  Culture  Collection  (Rockville,  MD).  3,  39-
Dioctadecyloxacarbocyanine perchlorate (DiO; Sigma, St. Louis, MO) was dissolved in dimethyl 
sulfoxide (Sigma, St. Louis, MO) to a concentration of 3 mM. Aliquots were frozen at -30° C 
and thawed for each experiment. RPMI media with and without phenol red were obtained from 
Gibco (Carlsbad, CA). Complete medium (CM) consisted of RPMI medium supplemented with 
10% fetal bovine serum, 100 U/ml penicillin, and 100 μg/ml streptomycin. Propidium iodide (PI) 
(Sigma, St. Louis, Mo.) was dissolved in CM to obtain a working solution of 10 mg/100 ml.  
Fetal bovine serum was obtained from Cellgro (Manassas, VA). 
Effector (PBMC) and target cells (10,000 cells) were added to tubes to create effector-to-
target (E:T) ratios within a range from 25:1 to 6.25:1. A total of 130 µl of PI was added, and the 
tubes were centrifuged for 30 seconds at 1,000 g to pellet the effector and target cells together in 
the presence of the PI. These cell mixtures were incubated for 2 hours at 37° C in a 5% CO2 
incubator. Controls consisted of target cells only plus PI and effector cells only plus PI and were 
set-up to detect spontaneous lysis and nonviable effector cells, respectively. After the cells were 
incubated  together,  they  were  analyzed  by  flow  cytometry.  The  forward  and  side-scatter 
parameters were adjusted to accommodate the inclusion of both target and effector cells within 
the acquisition gate to acquire a total of 20,000 events. Data were analyzed using CellQuest pro 
software (BD Biosciences, San Jose, CA). Percent lysis was calculated as:  percent lysis = [Cells 
positive for both DiO and PI/Total DiO labeled cells] * 100. The same equation was used to 
calculate  the  percent  spontaneous  lysis  for  the  sample  containing  only  target  cells.  The 
spontaneous lysis was subtracted from the experimental values for each sample. 
Multiplex  Cytokine  and  Growth  Factor  Testing.  Due  to  their  central  role  as  signaling 
compounds in the immune system, cytokines and growth factors are involved in a variety of 
immunological, inflammatory, and infectious diseases. New microarray based biochip cytokine 
technologies combine the latest technological advances with innovative system design to present 
a fully-automated system for rapid multiplex testing. It enables up to 12 cytokines and growth 
factors to be detected simultaneously in a single sample, providing valuable information related 
to  each molecule being tested and possible associations  between them in  each sample. This 
system saves time, costs, and resources and also provides high-quality, reliable results. 
Cytokine and growth factor levels in plasma specimens were measured using a biochip array 
system,  Evidence  Investigator
TM  (Randox  Laboratories  Ltd.,  Crumlin,  UK)  as  reported 
previously [13]. The testing platform consists of biochips secured in the base of a well placed in 
a  carrier  holding  nine  biochips  in  a  3 × 3  format.  Each  biochip  is  coated  with  the  capture 
antibodies specific for each of the 12 cytokines and growth factors (IL-2, IL-4, IL-6, IL-8, IL-10, 
IL-1α, IL-1β, IFN-γ, TNF-α, MCP-1, vascular endothelial growth factor [VEGF], and epidermal 
growth  factor  [EGF])  on  a  particular  test  region.  A  sandwich  chemiluminescent  assay  was Functional Foods in Health and Disease 2012, 2(7):265-279                                                            Page 269 of 279 
performed  with  100 μl  plasma  using  reagents  (including  the  calibrators  and  controls)  and 
protocols supplied by the same manufacturer. The light signal generated from each of the test 
regions on the biochip was detected using a charge-coupled detector camera and imaging system 
and compared with a calibration curve generated with known standards during the same run. All 
specimens were run in duplicate, and the concentration of a cytokine present in each plasma 
specimen was calculated from the standard curve and reported in pg/ml. 
Statistical  Analysis.  Data  were  analyzed  using  SPSS  19  (IBM  Inc.,  Chicago,  IL)  for 
Windows.  Frequency  and  descriptive  statistics  were  calculated  on  all  variables.  We  used 
repeated-measures analysis of variance (ANOVA) to examine the interaction effect of group (1 
gram/day versus 3 gram/day) by time (baseline, 48 hours, 1 week, 30 days, and 60 days) for 
NKCC, and for cytokines, growth factors, creatinine, total bilirubin, total protein, ALT, AST, 
and ALP the time factor was baseline, 1 week, 30 days, and 60 days. We first examined the 
interaction effect of the differences between group values across time. If no interaction effect 
was found, we then determined if the main effects of time and group were significant for the 
entire  sample.  A  statistically  significant  interaction  or  the  main  effect  of  time  was  further 
examined using simple effects pairwise t-tests. We used the ώ Huynh-Feldt correction factor to 
adjust the degrees of freedom for the averaged tests of significance, as the most conservative test 
of the repeated measures effect. The criterion for statistical significance was α = 0.05. 
 
RESULTS 
Safety Measures.  Table 1 shows creatinine, total protein, total bilirubin, ALT, AST, and ALP for 
both groups. No significant differences were observed for any of these measures between the two 
groups from baseline to 60 days. For the 1 gram/day group, no subject’s creatinine value was 
higher than 0.3 mg/dL more than the upper limit (< 1.5 standard deviation [SD] from the mean 
[M]), and no value was less than the lower limit. Total protein and total bilirubin were within the 
reference range at all time points. All ALP values were within the reference range, except for 1 
value -2 U/L at 60 days. All AST values were within the reference range, except for 1 value -4 
U/L at 1 week. All ALT values were within the reference range. For the 3 gram/day group, no 
subject’s creatinine value was higher than 0.39 mg/dL more than the upper limit (< 1.5 SD from 
the M), and no value was less than the lower limit. Total protein was within the reference range 
at all time points. No total bilirubin value was higher than 0.5 mg/dL more than the upper limit 
(< 2.5 SD from the M). One ALP value was +4 U/L at baseline, 1 value was +3 U/L at 30 days, 
and 1 value was +4 U/L at 60 days. One AST value was +5 U/L at baseline, 1 value was +4 U/L 
at 1 week, 1 value was +41 U/L at 30 days, and 1 value was +3 U/L at 60 days (the first value 
was 1 subject, and the last 3 values were 1 subject). All ALT values were within the reference 
range, except for 1 subject, who had values of +4, +5, +13, +26, and +17 U/L for all time points, 
respectively. 
 
Table 1. Creatinine, Protein, Bilirubin, Alanine Transaminase, Aspartate Aminotransferase, and 
Alkaline Phosphatase at Baseline through 60 Days 
 
Measure  Time  Total Sample (n=20)  1 Gram/Day (n=10)  3 Gram/Day (n=10) 
Creatinine  Baseline  0.90±0.24 (0.59, 1.42)  0.86±0.21 (0.59, 1.23)  0.94±0.27 (0.66, 1.42) Functional Foods in Health and Disease 2012, 2(7):265-279                                                            Page 270 of 279 
(mg/dL)  1 Week  0.90±0.22 (0.60, 1.41)  0.86±0.17 (0.66, 1.29)  0.95±0.26 (0.60, 1.41) 
30 Days  0.90±0.22 (0.60, 1.37)  0.81±0.17 (0.63, 1.11)  1.00±0.24 (0.60, 1.37) 
60 Days  0.86±0.21 (0.62, 1.36)  0.85±0.21 (0.62, 1.36)  0.88±0.23 (0.62, 1.22) 
Total  Protein 
(g/dL) 
Baseline  7.4±0.4 (6.7, 8.1)  7.4±0.4 (6.8, 8.0)  7.4±0.4 (6.7, 8.1) 
1 Week  7.6±0.5 (6.6, 8.2)  7.7±0.4 (7.2, 8.1)  7.5±0.6 (6.6, 8.2) 
30 Days  7.3±0.5 (6.7, 8.3)  7.3±0.4 (6.8, 7.9)  7.4±0.5 (6.7, 8.3) 
60 Days  7.2±0.4 (6.6, 8.0)  7.2±0.2 (6.9, 7.6)  7.1±0.5 (6.6, 8.0) 
Total 
Bilirubin 
(mg/dL) 
Baseline  0.61±0.28 (0.3, 1.4)  0.48±0.08 (0.3, 0.6)  0.73±0.36 (0.4, 1.4) 
1 Week  0.61±0.23 (0.4, 1.2)  0.52±0.12 (0.4, 0.8)  0.69±0.29 (0.4, 1.2) 
30 Days  0.62±0.33 (0.3, 1.6)  0.47±0.13 (0.3, 0.7)  0.76±0.41 (0.3, 1.6) 
60 Days  0.58±0.32 (0.3, 1.7)  0.53±0.17 (0.3, 0.8)  0.63±0.42 (0.3, 1.7) 
Alanine 
Transaminase 
(U/L) 
Baseline  17.4±8.6 (8, 44)  16.5±6.9 (8, 30)  18.2±10.3 (9, 44) 
1 Week  19.5±10.4 (8, 53)  19.1±8.3 (11, 31)  19.9±12.7 (8, 53) 
30 Days  18.3±12.6 (8, 66)  15.9±6.5 (9, 28)  20.7±16.8 (8, 66) 
60 Days  18.4±12.2 (7, 57)  17.3±9.0 (8, 37)  19.5±15.2 (7, 57) 
Aspartate 
Aminotransfer
ase (U/L) 
Baseline  20.9±6.0 (12, 35)  20.7±5.5 (12, 28)  21.1±6.6 (16, 35) 
1 Week  21.7±7.8 (6, 38)  21.1±8.9 (6, 38)  22.3±7.0 (15, 34) 
30 Days  23.6±12.2 (13, 71)  19.9±5.1 (13, 28)  27.2±16.1 (15, 71) 
60 Days  19.7±5.9 (10, 33)  19.6±5.7 (10, 30)  19.7±5.7 (10, 30) 
Alkaline 
Phosphatase 
(U/L) 
Baseline  65.6±22.4 (38, 119)  61.8±21.1 (38, 93)  69.4±24.1 (38, 119) 
1 Week  67.4±21.7 (36, 113)  64.3±19.7 (41, 94)  70.4±24.1 (36, 113) 
30 Days  67.5±22.2 (37, 118)  63.6±17.0 (37, 89)  71.4±26.7 (41, 118) 
60 Days  65.3±22.5 (31, 119)  60.8±18.8 (31, 85)  69.8±25.8 (39, 119) 
 
  NOTE: Values are mean ± standard deviation (minimum, maximum). 
 
NKCC.  Figure 1 shows the changes in NKCC for both groups from baseline to 60 days.  We 
found  a  significant  effect  for  time  (F[3.0,54.0]  =  7.2,  p  =  0.001),  but  the  group  by  time 
interaction (p = 0.85) and the main effect  of  group (p = 0.48)  were non-significant.  The ώ 
degrees of freedom Huynh-Feldt correction factor for the within-subjects effects was 1.000. For 
the  total  sample,  NKCC  peaked  at  1  week  (M  =  30.24;  standard  error  [SE]  =  2.07,  95% 
confidence  interval  [CI]:  25.88,  34.56)  and  was  significantly  higher  than  the  baseline  (M  = 
22.38; SE = 2.31, 95% CI: 17.52, 27.24; p = 0.016), 48 hour (M = 23.86; SE = 2.13, 95% CI: Functional Foods in Health and Disease 2012, 2(7):265-279                                                            Page 271 of 279 
19.38, 28.34; p = 0.028), 30 day (M = 20.32; SE = 1.71, 95% CI: 16.73, 23.91; p = 0.001), and 
60 day (M = 20.32; SE = 2.51, 95% CI: 15.05, 25.59; p = 0.001) values. No other values were 
significantly different among the others. 
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Figure 1.  NK Cell Cytotoxicity from Baseline to 60 Days 
 
NKCC (Percent Lysis) at Baseline, 48 Hours, 1 Week, 30 Days, and 60 Days was measured by 
flow cytometric assay. As shown and described in the text, NKCC peaked at 1 week and was 
significantly higher than all other values and even declined below the baseline value at the 30 
and 60 day follow-up assessments. 
 
Cytokines and Growth Factors.  Table 2 shows the descriptive values for all 12 cytokines 
and growth factors at baseline, 1 week, 30 days, and 60 days for the entire sample and both 
groups. We found no significant effects for IL-4 and IL-8. 
 
Table 2. Cytokines and Growth Factors at Baseline through 60 Days 
 
Measure  Time  Total Sample (n=20)  1 Gram/Day (n=10)  3 Gram/Day (n=10) 
IL-2 
(pg/mL) 
Baseline  3.94±4.04 (0.00, 17.85)  3.33±5.46 (0.00, 17.85)  4.56±1.96 (3.29, 9.96) 
1 Week  2.65±2.62 (0.00, 9.61)  3.47±2.97 (0.00, 9.61)  1.83±2.03 (0.00, 4.55) 
30 Days  3.31±2.42 (0.00, 7.07)  3.60±2.67 (0.00, 7.07)  3.02±2.26 (0.00, 6.64) 
60 Days  5.53±2.74 (0.00, 9.51)  5.51±3.17 (0.00, 9.51)  5.55±2.40 (0.00, 9.18) 
IL-4 
(pg/mL) 
Baseline  1.50±1.68 (0.00, 6.84)  1.85±2.15 (0.00, 6.84)  1.16±1.02 (0.00, 2.54) 
1 Week  1.93±2.90 (0.00, 12.48)  2.65±3.74 (0.00, 12.48)  1.21±1.63 (0.00, 4.20) 
30 Days  1.49±1.23 (0.00, 3.65)  1.57±1.47 (0.00, 3.65)  1.41±1.02 (0.00, 2.78) Functional Foods in Health and Disease 2012, 2(7):265-279                                                            Page 272 of 279 
60 Days  0.75±1.74 (0.00, 6.88)  1.49±2.28 (0.00, 6.88)  0.00±0.00 (0.00, 0.00) 
IL-6 
(pg/mL) 
Baseline  0.90±1.10 (0.00, 5.21)  1.22±1.41 (0.58, 5.21)  0.57±0.76 (0.00, 1.41) 
1 Week  0.48±0.70 (0.00, 2.89)  0.71±0.90 (0.00, 2.89)  0.26±0.37 (0.00, 0.87) 
30 Days  0.82±0.48 (0.00, 1.48)  0.89±0.38 (0.00, 1.30)  0.75±0.57 (0.00, 1.48) 
60 Days  0.40±0.67 (0.00, 2.15)  0.53±0.75 (0.00, 2.15)  0.27±0.59 (0.00, 1.66) 
IL-8 
(pg/mL) 
Baseline  6.50±7.74 (1.92, 35.60)  7.74±10.18 (2.30, 35.60)  5.26±4.43 (1.92, 16.90) 
1 Week  3.53±3.36 (0.00, 13.80)  3.74±4.14 (0.00, 13.80)  3.31±2.58 (0.00, 6.90) 
30 Days  6.81±6.93 (0.00, 25.10)  6.49±3.44 (0.00, 10.90)  7.12±9.45 (0.00, 25.10) 
60 Days  3.13±3.82 (0.00, 12.20)  2.67±3.82 (0.00, 12.20)  3.60±3.97 (0.00, 9.02) 
IL-10 
(pg/mL) 
Baseline  0.67±1.32 (0.00, 5.76)  0.49±0.66 (0.00, 1.75)  0.85±1.78 (0.00, 5.76) 
1 Week  0.22±0.32 (0.00, 0.90)  0.21±0.35 (0.00, 0.90)  0.23±0.30 (0.00, 0.60) 
30 Days  0.83±0.55 (0.00, 2.12)  1.05±0.51 (0.00, 2.12)  0.60±0.52 (0.00, 1.19) 
60 Days  0.25±0.83 (0.00, 3.44)  0.15±0.49 (0.00, 1.54)  0.34±1.09 (0.00, 3.44) 
IL-1α 
(pg/mL) 
Baseline  0.56±0.51 (0.00, 1.92)  0.63±0.57 (0.00, 1.92)  0.48±0.46 (0.00, 1.13) 
1 Week  0.13±0.24 (0.00, 0.90)  0.16±0.30 (0.00, 0.90)  0.11±0.18 (0.00, 0.49) 
30 Days  0.64±0.56 (0.00, 2.28)  0.90±0.59 (0.00, 2.28)  0.38±0.42 (0.00, 1.00) 
60 Days  0.14±0.28 (0.00, 0.80)  0.14±0.29 (0.00, 0.80)  0.13±0.28 (0.00, 0.73) 
IL-1β 
(pg/mL) 
Baseline  3.41±2.24 (0.00, 8.84)  3.51±1.99 (0.00, 6.87)  3.32±2.57 (0.00, 8.84) 
1 Week  1.69±2.54 (0.00, 8.60)  1.91±2.56 (0.00, 8.15)  1.46±2.63 (0.00, 8.60) 
30 Days  3.64±2.65 (0.00, 8.55)  3.63±2.19 (0.00, 7.02)  3.64±3.16 (0.00, 8.55) 
60 Days  0.49±1.22 (0.00, 4.11)  0.41±1.30 (0.00, 4.11)  0.57±1.21 (0.00, 3.19) 
IFN-γ 
(pg/mL) 
Baseline  0.56±1.04 (0.00, 3.39)  0.72±1.22 (0.00, 3.39)  0.40±0.86 (0.00, 2.21) 
1 Week  0.50±1.02 (0.00, 3.67)  0.53±0.90 (0.00, 2.46)  0.48±1.17 (0.00, 3.67) 
30 Days  1.86±1.89 (0.00, 7.09)  1.38±1.23 (0.00, 3.09)  2.35±2.35 (0.00, 7.09) 
60 Days  0.33±1.07 (0.00, 4.29)  0.43±1.36 (0.00, 4.29)  0.23±0.74 (0.00, 2.34) 
TNF-α 
(pg/mL) 
Baseline  1.78±0.88 (0.00, 3.00)  1.73±0.86 (0.00, 2.90)  1.84±0.95 (0.00, 3.00) 
1 Week  1.41±1.19 (0.00, 3.80)  1.34±1.32 (0.00, 3.80)  1.49±1.11 (0.00, 3.60) 
30 Days  1.79±1.49 (0.00, 6.19)  2.07±1.14 (1.03, 4.93)  1.51±1.80 (0.00, 6.19) 
60 Days  0.86±1.58 (0.00, 4.65)  0.67±1.44 (0.00, 3.90)  1.05±1.76 (0.00, 4.65) 
MCP-1 
(pg/mL) 
Baseline  60.72±21.88 (21.71, 103.70)  63.58±19.93 (37.28, 103.70)  57.86±24.41 (21.71, 92.66) 
1 Week  71.48±24.85 (22.01, 113.17)  73.17±26.12 (42.64, 113.17)  69.79±24.80 (22.01, 101.67) 
30 Days  81.86±41.75 (29.15, 183.97)  83.27±33.02 (37.72, 130.36)  80.46±50.85 (29.15, 183.97) 
60 Days  86.45±25.94 (38.93, 138.57)  84.14±14.38 (52.97, 102.34)  88.77±34.66 (38.93, 138.57) 
VEGF 
(pg/mL) 
Baseline  45.13±35.96 (12.47, 142.40)  41.19±30.29 (13.41, 97.91)  49.06±42.16 (12.47, 142.40) 
1 Week  29.27±32.00 (0.00, 126.02)  18.98±19.64 (0.00, 51.95)  39.56±39.23 (0.00, 126.02) 
30 Days  40.28±38.33 (0.00, 159.40)  42.42±33.27 (12.94, 120.20)  38.13±44.54 (0.00, 159.40) 
60 Days  24.06±23.66 (0.00, 82.56)  16.64±13.06 (0.00, 38.65)  31.47±29.82 (0.00, 82.56) 
EGF 
(pg/mL) 
Baseline  32.90±41.90 (4.33, 174.94)  27.14±27.62 (6.88, 93.65)  38.66±53.58 (4.33, 174.94) 
1 Week  11.62±14.35 (0.00, 60.31)  8.06±8.60 (1.55, 22.60)  15.18±18.23 (0.00, 60.31) 
30 Days  53.49±52.67 (2.18, 211.90)  58.86±41.19 (2.18, 127.13)  48.13±64.00 (3.67, 211.90) 
60 Days  14.70±12.29 (0.00, 48.73)  13.76±10.18 (2.80, 31.74)  15.64±14.61 (0.00, 48.73) 
 
NOTE: Values are mean ± standard deviation (minimum, maximum). 
 
For IL-2, a significant effect was found for time (F[2.7,47.7] = 3.3, p = 0.037), but the group by 
time interaction (p = 0.51) and the main effect of group (p = 0.72) were non-significant.  The ώ 
degrees  of  freedom  Huynh-Feldt  correction  factor  for  the  within-subjects  effects  was  0.884. 
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6.85) was significantly higher than the 1 week (M = 2.65; SE = 0.57, 95% CI: 1.45, 3.85; p = 
0.001) and 30 day (M = 3.31; SE = 0.55, 95% CI: 2.15, 4.47; p = 0.016) values. No other values 
were significantly different. 
For IL-6, a significant effect was found for time (F[2.6,47.5] = 3.5, p = 0.028), but the group 
by time interaction (p = 0.53) and main effect of group (p = 0.15) were non-significant.  The ώ 
degrees of freedom Huynh-Feldt correction factor for the within-subjects effects was 0.880. For 
the total sample, IL-6 decreased at 1 week, increased at 30 days, and decreased again at 60 days, 
and further pairwise comparisons revealed that the value at baseline (M = 0.90; SE = 0.24, 95% 
CI: 0.39, 1.40) was significantly higher than the 1 week (M = 0.48; SE = 0.15, 95% CI: 0.16, 
0.80; p = 0.027) and 60 day (M = 0.40; SE = 0.15, 95% CI: 0.08, 0.72; p = 0.014) values, and the 
30 day value (M = 0.82; SE = 0.11, 95% CI: 0.60, 1.05) was significantly higher than the 60 day 
value (p = 0.013). No other values were significantly different. 
For IL-10, a significant effect was found for time (F[1.5,27.4] = 3.9, p = 0.04), but the group 
by time interaction (p = 0.28) and main effect of group (p = 0.91) were non-significant.  The ώ 
degrees  of  freedom  Huynh-Feldt  correction  factor  for  the  within-subjects  effects  was  0.507. 
Pairwise comparisons revealed that the value at 1 week (M = 0.22; SE = 0.73, 95% CI: 0.07, 
0.38) was significantly lower than the 30 day value (M = 0.83; SE = 0.12, 95% CI: 0.58, 1.07), 
and the 60 day value (M = 0.25; SE = 0.19, 95% CI: -0.15, 0.65) was significantly lower than the 
baseline (M = 0.67; SE = 0.30, 95% CI: 0.04, 1.30; p = 0.009) and 30 day (p = 0.007) values. No 
other values were significantly different. 
For IL-1α, a significant effect was found for time (F[2.2,40.4] = 11.7, p = 0.001), but the 
group by time interaction (p = 0.12) and main effect of group (p = 0.16) were non-significant.  
The ώ  degrees  of freedom  Huynh-Feldt correction  factor for the within-subjects  effects  was 
0.748. Pairwise comparisons revealed that the value at baseline (M = 0.56; SE = 0.12, 95% CI: 
0.31, 0.80) was significantly higher than at 1 week (M = 0.13; SE = 0.06, 95% CI: 0.02, 0.25; p < 
0.001) and at 60 days (M = 0.14; SE = 0.06, 95% CI: 0.01, 0.27; p < 0.001), and the value at 30 
days (M = 0.64; SE = 0.11, 95% CI: 0.40, 0.88) was significantly higher than at 1 week (p = 
0.001) and at 60 days (p = 0.001). No other values were significantly different. 
For IL-1β, a significant effect was found for time (F[2.7,48.2] = 11.8, p = 0.001), but the 
group by time interaction (p = 0.95) and main effect of group (p = 0.87) were non-significant.  
The ώ  degrees  of freedom  Huynh-Feldt correction  factor for the within-subjects  effects  was 
0.893. Pairwise comparisons revealed that the value at 1 week (M = 1.69; SE = 0.58, 95% CI: 
0.47, 2.91) was significantly lower than at baseline (M = 3.41; SE = 0.51, 95% CI: 2.33, 4.49; p 
= 0.009) and at 30 days (M = 3.64; SE = 0.61, 95% CI: 2.36, 4.91; p = 0.03) and significantly 
higher than at 60 days (M = 0.49; SE = 0.28, 95% CI: -0.10, 1.08; p < 0.04). The value at 60 
days was significantly lower than at baseline (p < 0.001) and 30 days (p < 0.001). No other 
values were significantly different. 
For IFN-γ, a significant effect was found for time (F[2.0,36.6] = 6.9, p = 0.003), but the 
group by time interaction (p = 0.32) and main effect of group (p = 0.78) were non-significant.  
The ώ  degrees  of freedom  Huynh-Feldt correction  factor for the within-subjects  effects  was 
0.677. IFN-γ peaked at the 30-day assessment (M = 1.86; SE = 0.42, 95% CI: 0.98, 2.75), which 
was significantly higher than the baseline (M = 0.56; SE = 0.24, 95% CI: 0.06, 1.06; p = 0.017), Functional Foods in Health and Disease 2012, 2(7):265-279                                                            Page 274 of 279 
1 week (M = 0.50; SE = 0.23, 95% CI: 0.01, 1.00; p = 0.012), and 60 day (M = 0.33; SE = 0.24, 
95% CI: -0.18, 0.85; p = 0.003) values. No other values were significantly different. 
For TNF-α, a significant effect was found for time (F[2.9,51.6] = 3.8, p = 0.017), but the 
group by time interaction (p = 0.48) and main effect of group (p = 0.97) were non-significant.  
The ώ  degrees  of freedom  Huynh-Feldt correction  factor for the within-subjects  effects  was 
0.956. Pairwise comparisons revealed that the value at 60 days (M = 0.86; SE = 0.36, 95% CI: 
0.11, 1.62) was significantly lower than the baseline (M = 1.78; SE = 0.20, 95% CI: 1.36, 2.21; p 
= 0.012) and 30 day (M = 1.79; SE = 0.34, 95% CI: 1.08, 2.50; p = 0.037) values. No other 
values were significantly different. 
For MCP-1, a significant effect was found for time (F[2.1,37.8] = 3.9, p = 0.026), but the 
group by time interaction (p = 0.87) and main effect of group (p = 0.85) were non-significant.  
The ώ  degrees  of freedom  Huynh-Feldt correction  factor for the within-subjects  effects  was 
0.700.  MCP-1  peaked  at  60  days  (M  =  86.45;  SE  =  5.93,  95%  CI:  73.98,  98.92)  and  was 
significantly higher than the baseline (M = 60.72; SE = 4.98, 95% CI: 50.25, 71.18; p = 0.001) 
and 1 week (M = 71.48; SE = 5.70, 95% CI: 59.51, 83.44; p = 0.05) values. No other values were 
significantly different. 
For VEGF, a significant effect was found for time (F[2.6,47.3] = 4.8, p = 0.007), but the 
group by time interaction (p = 0.38) and main effect of group (p = 0.45) were non-significant.  
The ώ  degrees  of freedom  Huynh-Feldt correction  factor for the within-subjects  effects  was 
0.877. Pairwise comparisons revealed that the value at baseline (M = 45.13; SE = 8.21, 95% CI: 
27.88, 62.37) was significantly higher than the 1 week (M = 29.27; SE = 6.94, 95% CI: 14.70, 
43.85; p = 0.02) and 60 day (M = 24.06; SE = 5.15, 95% CI: 13.24, 34.87; p = 0.007) values. No 
other values were significantly different. 
For EGF, a significant effect was found for time (F[2.1,38.0] = 7.8, p = 0.001), but the group 
by time interaction (p = 0.63) and main effect of group (p = 0.82) were non-significant.  The ώ 
degrees  of  freedom  Huynh-Feldt  correction  factor  for  the  within-subjects  effects  was  0.703. 
Pairwise comparisons revealed that the value at baseline (M = 32.90; SE = 9.53, 95% CI: 12.88, 
52.92; p = 0.034) was significantly higher than 1 week (M = 11.62; SE = 3.19, 95% CI: 4.92, 
18.32) and 60 days (M = 14.70; SE = 2.82, 95% CI: 8.79, 20.61). The value at 30 days (M = 
53.49; SE = 12.03, 95% CI: 28.21, 78.78) was significantly higher than at 1 week (p = 0.001) 
and 60 days (p = 0.004). No other values were significantly different. 
 
DISCUSSION 
The ability of individuals to defend against infectious diseases and restrict the progression of 
carcinogenesis depends upon both immunity and nutritional factors. Immune surveillance is an 
important  host  protection  function,  specifically  as  it  serves  to  inhibit  the  progression  of 
carcinogenesis and viral infection. Several immune effector cells and secreted cytokines play 
critical  roles  in  the  overall  process.  The  enhancement  of  NKCC  by  RBAC  is  expected  to 
translate into enhanced immune surveillance. 
In  the  current  study,  RBAC  demonstrated  significant  immunomodulatory  activity  based 
upon the observed changes  in  NKCC and the  cytokines and  growth  factors. Our results  are 
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positively  impact  immune  system  functioning  [6-8].  RBAC  action  was  rapid  enough  to 
significantly enhance NKCC within 1 week of administration in RBAC-naïve adult subjects.  
Following its peak at 1 week, NKCC declined to baseline levels by 30 days. The increase in 
NKCC appears to be due to an increase in NK activity on a per-cell basis, rather than due to an 
increase in the actual NK cell number. This is supported by our finding that lower E:T ratios of 
12.5:1 and 25:1 were highly effective against K562 cell lysis. 
Nine out of 12 cytokines and growth factors showed changes over time for the total sample 
(no difference between groups), specifically between baseline, 1 week, and 30 and 60 days. The 
Th1 cytokine profile showed that IL-2, IFN-γ, and TNF-α decreased at 1 week, but significantly 
increased at 30 days for IFN-γ and TNF-α and at 60 days for IL-2. Most of the Th2 cytokines, 
including IL-10, showed an initial decline at 1 week and then returned to baseline levels by 30 
days similar to the trend observed with Th1 cytokines. 
IL-4 was the only cytokine that increased in the first week of RBAC administration. This 
period  corresponds  directly  with  the  time  course  of  the  NKCC  spike.  As  IL-4  is  a  potent 
regulator of  NKCC, the potential exists  that the NKCC enhancing  effect  of RBAC  is  IL-4-
mediated. MCP-1 was the only cytokine that continuously increased during the intervention.  
MCP-1 is a pro-inflammatory chemokine, functioning as a chemoattractant and NK cell activator 
[14;15]. MCP-1 has been shown to induce migration of activated NK cells in vitro [16]. RBAC 
promotion of MCP-1 release may act to enhance NK cell access to sites of infection and/or 
malignant  proliferation.  Additional  studies  are  needed  to  assess  the  potential  of  selective 
upregulation of effector cell chemokine receptors following RBAC intake. 
It is important to note that in our study of RBAC in healthy adults we detected responses 
that  were  not  solely  immunostimulatory  or  immunosuppressive.  Rather,  our  trial  showed 
transient,  bi-directional  immune  marker  effects  consistent  with  true  multifactorial 
immunomodulation. When given an immunomodulator, it may be postulated that the immune 
system  becomes  alert  to  the  existing  infections  and  disorders  within  the  body.  In  a  healthy 
normal adult, the infectious and toxic presence within the body may be small enough that an 
optimally functioning immune system can eliminate it relatively quickly. Therefore, the NKCC 
and other immune activation parameters would show only a transient enhancement. In patients 
with functionally-compromised immunity (e.g., due to environmental factors or lifestyle habits) 
or serious illnesses (e.g., cancer, HIV/AIDS, or other life-threatening infections), the immune 
system  response  to  an  immunomodulator  would  need  to  be  prolonged  due  to  the  greater 
malignant, infectious, and toxic burdens present [17]. 
The importance of NKCC in controlling the progression of carcinogenesis is exemplified by 
the finding that some tumors employ mechanisms to confound NK immunosurveillance, e.g., 
production of decoy  NKG2D receptor ligands  [4]. Additionally, it has been established that 
depressed NKCC is associated with increased cancer risk; however the specific mechanisms of 
immunomodulation remain uncertain [18]. Development of effective therapeutic strategies will 
require  great  work  in  the  clarification  of  NKCC  in  vitro  and  in  vivo;  especially  in  the 
identification of specific NK receptor-activating ligands. 
Investigators  focused  on  bioactive  natural  products  have  identified  a  variety  of 
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have shown both innate and adaptive immune system effects, and polysaccharide receptors have 
been found on NK cells, T- and B-lymphocytes, macrophages, monocytes, and other effector 
cells [20]. Thus, RBAC fractions or isolates may potentially contain NK receptor ligands or 
analogous  molecular  species  that  could  be  used  as  experimental  probes.  Of  note,  the 
oligosaccharides present in the RBAC complex bear structural homology with sialyl Lewis x 
residues, which are known NK cell lectin-like receptor ligands and activators of NKCC [21;22].  
Additionally, oligosaccharide moieties may function as ligands for natural cytotoxicity receptors 
[23]. 
Research efforts are underway in several centers to exploit NK cell functions to improve the 
management  of  both  cancer  patients  and  patients  at  high-risk  for  the  development  of 
malignancies  [24].  Therapeutic  strategies  combining  agents  that  activate  anti-tumor  immune 
responses  with  cytotoxic  chemotherapeutic  agents  may  enhance  cancer  treatment  outcomes.  
Furthermore,  IL-2  produces  an  augmentation  in  NKCC  in  a  manner  similar  to  RBAC,  and 
combining the two agents may result in an additive or synergistic effect useful for the treatment 
of malignant melanoma and renal cell carcinoma. This is of particular interest, as it may allow 
for a decrease in the dosage of IL-2, thereby reducing toxicity without compromising therapeutic 
efficacy. Further elucidation of the cellular and molecular mechanisms involved in anti-tumor 
immune responses will be needed. 
Given that metastasis is the cause of 90% of cancer deaths in humans [25], RBAC or similar 
immunomodulators may allow for the development of truly preventive anti-cancer strategies by 
optimizing  NKCC.  This  could  potentially  enable  transformed  cells  at  clinically-undetectable 
stages  of  carcinogenesis  and  circulating  tumor  cells  (CTCs)  to  be  eliminated  prior  to  their 
development  into  primary or metastatic tumors.  This  carries significant  potential to  improve 
outcomes in clinical and surgical oncology, where patients have existent CTCs and/or develop 
CTCs secondary to mechanical disturbance of malignant tissues [26;27]. 
Thus,  the  results  of  our  study  suggest  that  RBAC  immunomodulation  merits  further 
investigation in humans; specifically in the presence of conditions where the immune system is 
challenged and/or functionally-compromised, e.g., tobacco smoking, influenza, HIV/AIDS, and 
cancer. We anticipate that RBAC may:  (a) facilitate the destruction of malignant and virus-
infected cells, (b) enhance immune effector cell activity, (c) optimize immune system function, 
and (d) improve host recovery, long-term health maintenance, and overall quality of life. 
Limitations.  The findings of this study are limited by a small sample size. A larger sample 
size could result in even more significant findings for NKCC, cytokines, and growth factors in 
addition to further strengthening the distinction in the results between the two dosage groups. It 
was not possible to objectively determine compliance with the protocol, as the composition of 
the RBAC complex does not readily lend itself to metabolite assessment.  Although we found the 
highest peak in NKCC at 1 week and in most of the cytokines and growth factors at 30 days, a 
follow-up period of 6 to 12 months with continued RBAC administration could elucidate the 
ability of RBAC to modulate immune system function over an extended period of time. 
 
CONCLUSIONS                                                                                                                             
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assessment without reporting any adverse event, and the assessments were completed in a timely 
fashion. The supplement was typically safe among subjects in both dosage groups according to 
measures of creatinine, total protein, total bilirubin, ALT, AST, and ALP. RBAC demonstrated 
sound immunomodulatory activity with significant responses in NKCC and nine out of twelve 
cytokines  and  growth  factors.  No statistical  differences  were found between the two dosage 
groups  in  the  measured  parameters.  Therefore,  the  two  dosages  recommended  by  the 
manufacturer of RBAC (i.e., 1 gram/day and 3 gram/day) would appear equivalent with respect 
to the observed effects on NKCC, cytokines, and growth factors in healthy adults. 
Our  study  showed  transient,  bidirectional,  immune  marker  effects  consistent  with  true 
multifactorial immunomodulation. An important tendency noted in the activity profiles of several 
natural product immunomodulators is that of “optimization” or true immunomodulation, rather 
than  simple  upregulation  or  downregulation  of  the  immune  response.  Thus,  a  healthy 
individual’s response to an immunomodulator  is expected to be distinctly different from the 
response during an illness like influenza, HIV/AIDS, or cancer. 
More studies are required to compare the role of NKCC and the cytokine and growth factor 
profile following RBAC intake to further delineate the selective and sustained NK activation 
property  of  RBAC.  Finally,  the  results  of  this  study  in  healthy  subjects  suggest  that  the 
immunomodulatory activity of RBAC should be studied in conditions where the human immune 
system  has  been  functionally-compromised:  e.g.,  tobacco  smoking,  cancer,  HIV/AIDS,  etc.  
RBAC  may  not  only  facilitate  destruction  of  tumor  and  virus-infected  cells,  but  may  also 
increase  immune  effector  cell  activity,  and  it  may  enhance  host  recovery,  long-term  health 
maintenance, and overall quality of life by optimizing immune system function. 
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